Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Posts Tagged ‘conferences’

Zendesk to Present at Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 5 agosto 2019

Marc Cabi, Vice President of Strategy and Head of Investor Relations, will present at the Oppenheimer 22nd Annual Technology, Internet & Communications Conference in Boston, Massachusetts on Tuesday, August 6, 2019. Zendesk’s presentation is scheduled for 1:05 p.m., Eastern Time. Marc Cabi, Vice President of Strategy and Head of Investor Relations, will present at the Canaccord Genuity Growth Conference in Boston, Massachusetts on Wednesday, August 7, 2019. Zendesk’s presentation is scheduled for 8:30 a.m., Eastern Time.
Shawna Wolverton, Senior Vice President, Product, will present at the KeyBanc Technology Investor Conference in Vail, Colorado on Tuesday, August 13, 2019. Zendesk’s presentation is scheduled for 1:00 p.m., Mountain Time.
A live webcast of each presentation will be accessible by visiting Zendesk’s investor website at investor.zendesk.com. An archived version will be available for six months.
The best customer experiences are built with Zendesk. Our customer service and engagement products are powerful and flexible, and scale to meet the needs of any business. Zendesk serves businesses across a multitude of industries, with more than 145,000 paid customer accounts offering service and support in over 30 languages. Zendesk is headquartered in San Francisco, and operates worldwide with 17 offices in North America, Europe, Asia, Australia, and South America. Learn more at http://www.zendesk.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Citrix Executives to Present at Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 5 agosto 2019

Citrix Systems, Inc. (NASDAQ:CTXS) today announced that executives will attend two upcoming investor conferences.Jessica Soisson, interim chief financial officer, will present at the Oppenheimer Technology, Internet and Communications Conference in Boston on August 6 at 9:05 a.m. Eastern.PJ Hough, executive vice president and chief product officer, will present at the Citi 2019 Global Technology Conference in New York on September 5 at 3:40 p.m. Eastern.
A webcast of each presentation will be available live on the investor section of the Citrix website at http://www.investors.citrix.com. A replay will be available for approximately 30 days.Citrix (NASDAQ:CTXS) is powering a better way to work with unified workspace, networking, and analytics solutions that help organizations unlock innovation, engage customers, and boost productivity, without sacrificing security. With Citrix, users get a seamless work experience and IT has a unified platform to secure, manage, and monitor diverse technologies in complex cloud environments. Citrix solutions are in use by more than 400,000 organizations including 99 percent of the Fortune 100 and 98 percent of the Fortune 500. Learn more at http://www.citrix.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Arcus Biosciences to Present at Upcoming Investor Conferences

Posted by fidest press agency su mercoledì, 31 luglio 2019

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate in the following upcoming investor conferences:
BTIG Biotechnology Conference on Monday, August 12, 2019, at 12:00 pm Eastern Time in New York. Juan Jaen, Ph.D., President, will participate in a panel discussion entitled, “Solid Tumors Beyond PD-1 Monotherapy.”
2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 8:35 am Eastern Time in New York. Juan Jaen, Ph.D., President, and Rekha Hemrajani, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat. To access the live audio webcast of the fireside chat, please visit the “Investors” section of the Arcus website at http://www.arcusbio.com. A replay of the webcast will be available for 30 days following the live event.
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is being evaluated in a Phase 1 trial as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 trial. Arcus has extensive in-house expertise in medicinal chemistry, oncology, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has developed a robust and active early-stage discovery effort focused on small-molecule pipeline expansion. For more information about Arcus Biosciences, please visit http://www.arcusbio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cirrus Logic to Present at Upcoming Conferences

Posted by fidest press agency su domenica, 21 luglio 2019

Boston, Aug. 6 – Cirrus Logic Chief Financial Officer Thurman Case and Vice President of Mixed-Signal Products Carl Alberty will present at the Oppenheimer Technology, Internet & Communications Conference at 10:25 a.m. EDT at the Four Seasons Hotel.
Vail, Colo., Aug. 12 – Cirrus Logic Chief Financial Officer Thurman Case and Vice President of Mixed-Signal Products Carl Alberty will present at the KeyBanc Capital Markets Annual Technology Leadership Forum at 2 p.m. MDT at the Hotel Talisa.
A live webcast of the presentations will be available on the company’s investor relations website, and an archived replay of the webcasts will be available on the website following the events.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

Posted by fidest press agency su martedì, 11 giugno 2019

Montreal Wednesday, June 19th at 1:15pm ET / 10:15am PT. The 2019 Bank of Montreal Prescriptions for Success Healthcare Conference on Tuesday, June 25th at 3:00pm ET / 12:00pm PT. Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the two investor conferences.
The presentations will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit http://www.fiveprime.com or follow us on LinkedIn, Twitter and Facebook.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Jefferies Global Healthcare Conference

Posted by fidest press agency su venerdì, 31 Mag 2019

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 at 1:30 PM ET in New York City.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Mastercard to Participate in Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 23 Mag 2019

Mastercard Incorporated (NYSE: MA) today announced its participation in the following investor conferences in the month of June:
On Wednesday, June 5, Sachin Mehra, chief financial officer, will present at the William Blair Growth Stock Conference in Chicago. The discussion will begin at 9:00 a.m. Eastern Time and last for approximately 30 minutes.
On Tuesday, June 11, Linda Kirkpatrick, executive vice president, Merchants & Acceptance, will present at the Morgan Stanley Financials Conference in New York City. The discussion will begin at 3:15 p.m. Eastern Time and last for approximately 40 minutes.There will be a live audio webcast of each discussion and replays will be archived for 30 days at http://www.mastercard.com/investor.
Mastercard (NYSE: MA), http://www.mastercard.com, is a technology company in the global payments industry. Our global payments processing network connects consumers, financial institutions, merchants, governments and businesses in more than 210 countries and territories. Mastercard products and solutions make everyday commerce activities – such as shopping, traveling, running a business and managing finances – easier, more secure and more efficient for everyone.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

Posted by fidest press agency su mercoledì, 22 Mag 2019

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that data has been accepted for presentation at both the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary and European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.“We are excited to present more Phase 1 data on KVD900, our oral plasma kallikrein inhibitor in development for on-demand treatment of hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Our Phase 2 clinical trial of KVD900 is still expected to have data late this year. We remain committed to providing options for patients to manage their disease with oral medicines.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Avalara to Present at Upcoming Investor Conferences

Posted by fidest press agency su venerdì, 10 Mag 2019

Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced the following upcoming investor conference presentations.
Co-Founder and Chief Executive Officer Scott McFarlane will present at the J.P. Morgan 47th Annual Global Technology, Media and Communications Conference in Boston on Thursday, May 16, 2019, at 10:40 a.m. ET (7:40 a.m. PT).
Chief Financial Officer Bill Ingram will present at the Needham Emerging Technology Conference in New York on Tuesday, May 21, 2019, at 1:50 p.m. ET (10:50 a.m. PT).
Live webcasts of the presentations will be available on the Avalara investor relations website at investor.avalara.com. Archived replays will be made available for a limited time at the same location following the presentations.
Avalara helps businesses of all sizes get tax compliance right. In partnership with leading ERP, accounting, ecommerce, and other financial management system providers, Avalara delivers cloud-based compliance solutions for various transaction taxes, including sales and use, VAT, GST, excise, communications, lodging, and other indirect tax types. Headquartered in Seattle, Avalara has offices across the U.S. and around the world in Canada, the U.K., Belgium, Brazil, and India. More information at http://www.avalara.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

New Relic to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 9 Mag 2019

New Relic, Inc. (NYSE: NEWR), provider of real-time insights for software-driven businesses, today announced that members of its management team will present at the following investor conferences: J.P. Morgan 47th Annual Global Technology, Media and Communications Conference in Boston on Thursday, May 16, 2019, at 8:40 a.m. ET.
Needham Emerging Technology Conference in New York on Wednesday, May 22, 2019, at 8:20 a.m. ET. Baird Global Consumer, Technology & Services Conference in New York on Thursday, June 6, 2019, at 12:50 p.m. ET.
Live webcasts of the presentations will be accessible from the investor relations page of the New Relic website at http://ir.newrelic.com. Following the events, replays will be made available at the same location.
New Relic provides the real-time insights that software-driven businesses need to innovate faster. New Relic’s cloud platform makes every aspect of modern software and infrastructure observable, so companies can find and fix problems faster, build high-performing DevOps teams, and speed up transformation projects. Learn why more than 50% of the Fortune 100 trust New Relic at newrelic.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

DBV Technologies to Attend Upcoming Investor Conferences

Posted by fidest press agency su sabato, 4 Mag 2019

Montrouge, France DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present at the following investor conferences in May 2019:
Daniel Tassé, Chief Executive Officer, and Kevin Trapp, Chief Commercial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV, on Tuesday, May 14, 2019, at 11:20am PT.Kevin Trapp, Chief Commercial Officer, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, May 30, 2019, at 10:30am PT.A live webcast of the presentation at the Bank of America Merrill Lynch 2019 Health Care Conference will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website within one hour after the event.
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 4 aprile 2019

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will present a corporate overview at the H. C. Wainwright and Company Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. GMT at the Grosvenor House JW Marriott Hotel in London, UK and at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 2:50 p.m. ET at the Westin Grand Central Hotel in New York City.Live audio webcasts of both presentations will be available on the Company’s website at https://tphase.gcs-web.com/events-presentations. The archived presentation will be available for 30 days.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase’s lead product XERAVATM is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical trials and TP-2846 which is in preclinical testing for acute myeloid leukemia. Please visit http://www.tphase.com for more company information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

bluebird bio to Present at Investor Conferences in March

Posted by fidest press agency su martedì, 12 marzo 2019

39th Annual Health Care Conference, Tuesday, March 12, at 8:40 am ET at the Boston Marriott Copley Place, Boston, MA
Barclays Global Healthcare Conference, Thursday, March 14, at 1:05 pm ET at the Loews Miami Beach Hotel, Miami Beach, FL
Alliance for Regenerative Medicine’s 7th Annual Cell & Gene Investor Day, Thursday, March 21, at 12:10 pm ET at the Metropolitan Club, New York, NYTo access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences.
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Aura Biosciences to Present at Upcoming Investor Conferences

Posted by fidest press agency su sabato, 9 marzo 2019

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences: Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA
Oppenheimer’s 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit http://www.aurabiosciences.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

Posted by fidest press agency su domenica, 3 marzo 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference (Keystone), Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.CD47/SIRPα interaction is a key checkpoint mechanism exploited by cancer cells to escape immunological surveillance. While CD47 is widely expressed in human cells, SIRPα, the CD47 inhibitory receptor, is mainly expressed in myeloid cells and neurons. ALX148, a CD47 blocker with an inactive Fc domain, is generally well tolerated and demonstrates anti-cancer activity in combination with trastuzumab and pembrolizumab in patients with anti-HER2 and checkpoint inhibitor resistant/refractory disease (SITC 2018, P335). Another approach to block this interaction is to target SIRPα.“Targeting the CD47/SIRPα pathway is an exciting new approach that shows promise in clinical trials. By targeting SIRPα, we can investigate the similarities and differences of an orthogonal strategy to inhibit this axis,” said Hong Wan, Ph.D., ALX Oncology’s Chief Scientific Officer. “Our panel of proprietary high affinity monoclonal antibodies provides diverse epitope coverage across the extracellular surface of SIRPα. These antibodies are cross-reactive to human, monkey and rodent SIRPα variants, which enables robust clinical translation. Importantly, these antibodies bind to all human SIRPα variants, a critical attribute for a global patient population.” ALX Oncology’s SIRPα antibodies enhance the antitumor activity of immune checkpoint inhibitors, with reduction of metastases, eradication of tumors, and acquisition of memory immune response in tumor-bearing mice with intact immune systems. The cellular immune response in syngeneic models shows that these SIRPα antibodies enhance innate and adaptive anti-cancer immunity, providing a rationale for combination with other immunotherapies. In an exploratory toxicology study in monkeys, the selected SIRPα antibodies demonstrate a favorable pharmacokinetic, target occupancy and tolerability profile.Together, these preclinical data provide a compelling rationale to advance the development of anti-SIRPα therapy for patients with cancer.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 28 febbraio 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
8th Annual Leerink Partners Global Healthcare Conference in New York on Friday, March 1, 2019 at 9 a.m. ET.
Cowen and Company 39th Annual Healthcare Conference in Boston on Tuesday, March 12, 2019 at 8 a.m. ET.
A live audio webcast of both presentations can be accessed on the Investors and Media section of the Dicerna website at http://www.investors.dicerna.com. Archived replays will be available on the Company’s website for a period of 90 days after each conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

RealPage to Participate in Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 25 febbraio 2019

RealPage, Inc. (NASDAQ:RP), a leading global provider of software and data analytics to the real estate industry, today announced that Steve Winn, Chairman and CEO, will present at the JMP Securities 2019 Technology Conference, to be held in San Francisco on February 26, 2019 at 2:30 p.m. PT. Winn will also present on behalf of RealPage at the Morgan Stanley Technology, Media & Telecom Conference, to be held in San Francisco on February 27, 2019 at 1:30 p.m. PT. Both presentations will be webcast live on the Investor Relations section of the Company’s Web site at http://www.realpage.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

ObsEva SA to Participate in Upcoming Investor Conferences

Posted by fidest press agency su domenica, 24 febbraio 2019

Geneva, Switzerland and Boston, ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in two upcoming investor conferences. The SVB Leerink Global Healthcare Conference taking place in New York February 27-March 1, 2019. ObsEva will present on Thursday, February 28, 2019, at 3 p.m. Eastern Time.
The Jefferies Global Healthcare Summit taking place in Zurich, Switzerland on March 8, 2019. ObsEva will present on Friday, March 8, 2019 at 3:45 p.m. Central European Time.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit http://www.ObsEva.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

New Relic to Present at Upcoming Investor Conferences

Posted by fidest press agency su domenica, 10 febbraio 2019

New Relic, Inc. (NYSE:NEWR), provider of real-time insights for software-driven businesses, today announced that Chief Financial Officer Mark Sachleben will present at the following upcoming investor conferences:
Goldman Sachs Technology and Internet Conference in San Francisco on Tuesday, February 12, 2019, at 11:00 a.m. PT.
JMP Securities Technology Conference in San Francisco on Tuesday, February 26, 2019, at 2:00 p.m. PT.
Morgan Stanley Technology, Media & Telecom Conference in San Francisco on Wednesday, February 27, 2019, at 2:40 p.m. PT.
Raymond James 40th Annual Institutional Investors Conference in Orlando on Wednesday, March 6, 2019, at 9:50 a.m. ET.
Live webcasts of the presentations will be accessible from the investor relations page of the New Relic website at http://ir.newrelic.com. Following the events, replays will be made available at the same location.
New Relic provides the real-time insights that software-driven businesses need to innovate faster. New Relic’s cloud platform makes every aspect of modern software and infrastructure observable, so companies can find and fix problems faster, build high-performing DevOps teams, and speed up transformation projects. Learn why more than 50% of the Fortune 100 trust New Relic at newrelic.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Zayo Executives to Present at December Investor Conferences

Posted by fidest press agency su domenica, 2 dicembre 2018

Zayo Group Holdings, Inc. (NYSE: ZAYO) announced today that executives from the company will present at two investor conferences in December. The links to the live webcasts for the conferences will be made available through the Investor Relations section of the Company’s website at: http://investors.zayo.com.Dan Caruso, chairman and CEO, will present at the UBS Global Media and Communications Conference at the Grand Hyatt in New York on Tuesday, December 4, 2018. The presentation will be webcast live at 9:30 a.m. EST.Matt Steinfort, CFO, will present at the Barclays Global Technology, Media and Telecommunications Conference at The Palace Hotel in San Francisco on Thursday, December 6, 2018. The presentation will be webcast live at 11:30 a.m. PST.
Zayo Group Holdings, Inc. (NYSE: ZAYO) provides communications infrastructure solutions, including fiber and bandwidth connectivity, colocation and cloud infrastructure to the world’s leading businesses. Customers include wireless and wireline carriers, media and content companies and finance, healthcare and other large enterprises. Zayo’s 130,000-mile network in North America and Europe includes extensive metro connectivity to thousands of buildings and data centers. In addition to high-capacity dark fiber, wavelength, Ethernet and other connectivity solutions, Zayo offers colocation and cloud infrastructure in its carrier-neutral data centers. Zayo provides users with flexible, customized solutions and self-service through Tranzact, an innovative online platform for managing and purchasing bandwidth. For more information, visit zayo.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »